Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Canakinumab treatment real world evidence in 3 monogenic periodic fever syndromes in 2009–2022: an interim analysis using the French JIR cohort database

Fig. 2

Evolution of canakinumab posology in MKD patients: overall (A), in patients who initiated canakinumab after health authority approval (B), in adult patients (C) and in pediatric patients (D). (HTA: Heath technology assessment; MKD: Mevalonate Kinase Deficiency; q4w: every 4 weeks; q5-7w: every 5 to 7 weeks; q8w: every 8 weeks)

Back to article page